Ohara, Mizuho
Ohara, Kenzo
Kumai, Takumi http://orcid.org/0000-0002-3411-671X
Ohkuri, Takayuki
Nagato, Toshihiro
Hirata-Nozaki, Yui
Kosaka, Akemi
Nagata, Marino
Hayashi, Ryusuke
Harabuchi, Shohei
Yajima, Yuki
Oikawa, Kensuke
Harabuchi, Yasuaki
Sumi, Yasuo
Furukawa, Hiroyuki
Kobayashi, Hiroya
Funding for this research was provided by:
Japan Society for the Promotion of Science (17K16884, 19K07452)
Article History
Received: 3 August 2019
Accepted: 16 February 2020
First Online: 21 February 2020
Compliance with ethical standards
:
: The authors declare that they have no conflict of interest.
: This study followed the principles of the Helsinki Declaration, and the study protocol was approved by the Asahikawa Medical University Institutional Ethics Committee (approval number #16040-3).
: All blood samples from healthy human volunteers and CRC patients (Asahikawa Medical University Hospital, 2016-2018) were obtained after obtaining written informed consent (Institutional Ethics Committee approval number #16040-3). The patients and healthy donors agreed to the use of their specimens and data for research and publication.
: The CRC cell lines SW480 and SW620 were purchased from KAC Co., Ltd. (Kyoto, Japan). Lung SCC cell lines Calu-1 and Jurkat (T cell lymphoma) were obtained from the American Type Culture Collection (ATCC, Manassas, VA). The gingival SCC cell line Sa-3 and lung large cell carcinoma cell line Lu65 were supplied by the RIKEN Bio-Resource Center (Tsukuba, Japan). The renal cell carcinoma cell line SW839 was obtained from the Cell Resource Center for Biomedical Research Institute of Development (Aging and Cancer, Tohoku University, Sendai, Japan). Cell authentication assays were performed by each company, and the cell passaging was no more than five times.